Fig. 1: Graphical outline of targeted therapies in breast cancer and the clinical utility of liquid biopsy profiling during the course of care. | Nature Communications

Fig. 1: Graphical outline of targeted therapies in breast cancer and the clinical utility of liquid biopsy profiling during the course of care.

From: Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer

Fig. 1

Liquid biopsies may be utilized in identifying targetable gene alterations and biomarkers for specific therapies across different subtypes of breast cancer as well as in monitoring therapy-associated implications on tumor evolution and treatment evasion. (SERD Selective Estrogen Receptor Degrader, SERM Selective Estrogen Receptor Modulator, TMB tumor mutational burden, MSI microsatellite instability, ICPI immune checkpoint inhibitor, ADC antibody-drug conjugate).

Back to article page